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ABSTRACT 35 
 36 
Drinking water can be contaminated with pharmaceuticals. However, it is uncertain whether this 37 
contamination can be harmful for the liver, especially during obesity. Hence, the goal of our study 38 
was to determine whetherchronic exposure to low doses of pharmaceuticals could have deleterious 39 
effects in livers of lean and obese mice. To this end, lean and ob/ob male mice were treated for 4 40 
months with a mixture of 11 drugs provided in drinking water at concentrations ranging from 10 to 41 
106 ng/l. At the end of the treatment, some liver and plasma abnormalities were observed in ob/ob 42 
mice treated with the cocktail containing 106 ng/l of each drug. For this dosage, a gene expression 43 
analysis by microarray showed altered expression of circadian genes (e.g. Bmal1, Dbp, Cry1) in 44 
lean and obese mice. RT-qPCR analyses carried out in all groups of animals confirmed that 45 
expression of 8 different circadian genes was modified in a dose-dependent manner. For some 46 
genes, a significant modification was observed for dosages as low as 102-103 ng/l. Drug mixture and 47 
obesity presented an additive effect on circadian gene expression. These data were validated in an 48 
independent study performed in female mice. Thus, our study showed that chronic exposure to trace 49 
pharmaceuticals disturbed hepatic expression of circadian genes, particularly in obese mice. 50 
Because some of the 11 drugs can be found in drinking water at such concentrations (e.g. 51 
acetaminophen, carbamazepine, ibuprofen) our data could be relevant in environmental toxicology, 52 
especially for obese individuals exposed to these contaminants. 53 
 54 
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Introduction 69 
 70 
Contamination of air, soil and water with pharmaceuticals and personal care products is currently 71 
a major concern for many countries. Indeed, such contamination could endanger the health of 72 
millionsof individuals, especially in the case of chronic and multiple exposures in sensitive 73 
populations (Sanderson, 2011). Regarding pharmaceuticals, it is noteworthy that the parent drugs 74 
and their metabolites are excreted by patients as waste and some people also get rid of unused 75 
pharmaceuticals in the toilets. Hence, all these pharmaceuticals can thereafter be found in water 76 
(Kasprzyk-Hordern et al., 2008; Mompelat et al., 2009). For instance, the following drugs were 77 
detected in tap water in several independent studies: acetaminophen (APAP), bezafibrate and other 78 
fibrates, caffeine, carbamazepine, cotinine (a nicotine metabolite), diazepam, diclofenac, 79 
erythromycin, flumequine, ibuprofen, phenazone (antipyrine), roxithromycin, salicylic acid and 80 
sulfamethoxazole (Daughton and Ternes, 1999; Halling-Sorensen et al., 1998; Heberer, 2002; 81 
Mompelat et al., 2009; Stackelberg et al., 2004; Webb et al., 2003; Ye and Weinberg, 2007; Yu et 82 
al., 2007; Zuccato et al., 2000). As reported in most of these investigations, these drugs were found 83 
in the drinking water at concentrations ranging generally between 1 and 20 ng/l. However, for some 84 
pharmaceuticals such as APAP, caffeine, carbamazepine, fibrates, ibuprofen and phenazone, several 85 
hundreds of ng/l were sometimes found in tap water (Daughton and Ternes, 1999; Mompelat et al., 86 
2009).   87 
Long-term exposure to drug contaminants could have deleterious consequence for some 88 
sensitive tissues, especially the liver. Indeed, liver expresses high levels of cytochromes P450 89 
(CYPs) that can transform drugs into toxic metabolites, which are able to induce oxidative stress, 90 
mitochondrial dysfunction and cell death (Aubert et al., 2012; Leung et al., 2012). It is also worthy 91 
to mention that recent investigations indicated that the liver could be particularly sensitive to drug-92 
induced toxicity in the context of obesity (Aubert et al., 2012; Fromenty, 2013).  93 
Taken all these data into consideration, the aim of the present study was to determine the long-94 
term hepatic effects of pharmaceutical contaminants in lean and obese ob/ob mice. These mice were 95 
treated for 4 months with a mixture of 11 drugs provided in drinking water at concentrations ranging 96 
from 10 to 106 ng/l. These drugs included APAP, caffeine, carbamazepine, cotinine, diclofenac, 97 
erythromycin, ibuprofen, phenazone, roxithromycin, salicylic acid and sulfamethoxazole. 98 
Importantly, all these molecules were previously detected in drinking water, as mentioned 99 
previously.  100 
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Materials and methods 101 
 102 
Animals and exposure to drugs.Five-week-old male C57BL/6J-+/+mice (wild-type, also referred to 103 
as lean mice) weighing 19 to 20g and C57BL/6J-ob/ob mice, weighing 28 to 32 g, were purchased 104 
from Janvier (Le-Genest-St-Isle, France) and housed in the animal house facility of Rennes 1 105 
University under a 12 h light-dark cycle.All mice were fed ad libitumon a normal diet bringing 2820 106 
kcal per kg of food (A04 biscuits; UAR,Villemoisson-sur-Orge, France). After 1 week of 107 
acclimatization,wild-type and ob/ob mice were further split into 7different groups that were treated 108 
or not with a drug cocktail containing 11 molecules at the following concentrations: 10, 102, 103, 109 
104, 105 and 106 ng/l. All these drugs (APAP, caffeine, carbamazepine, cotinine, diclofenac, 110 
erythromycin, ibuprofen, phenazone, roxithromycin, salicylic acid and sulfamethoxazole) were 111 
purchased from Sigma-Aldrich (St. Quentin-Fallavier, France). Considering the molecular weight of 112 
the molecules, 106 ng/l corresponded to concentrations ranging from 1.2 M for roxithromycin to 113 
7.2 M for salicylic acid. In a second independent series of investigations, five-week-old female 114 
C57BL/6J-+/+and C57BL/6J-ob/ob mice were purchased from Janvier (Le-Genest-St-Isle, France) 115 
and housed in the animal house facility of the Robert Debré Hospital. In this study, mice were 116 
treated or not with the same cocktail containing the 11 drugs at the following concentrations: 104, 117 
105 and 106 ng/l. For both studies conducted in Rennes and Paris, mice were exposed during 4 118 
months to these drugs by way of the drinking water, which was renewed every week. Because ob/ob 119 
mice are drinking more than lean mice (Fromenty et al. 2009; Massart et al. 2012), drug 120 
concentrations in the drinking water was adapted in the group of obese mice to keep constant the 121 
daily intake of the drugs between lean and obese mice. Consumption of water was monitored every 122 
week and it was not reduced by the presence of the mixture, whatever the drug concentrations.The 123 
last day of the treatment, blood was drawn in the morning between 10 a.m. and 2 p.m. Blood 124 
withdrawal was carried out from the retro orbital sinus with heparinized capillary Pasteur pipettes 125 
for biochemistry analyses. Mice were then sacrificed by cervical dislocation and liver was quickly 126 
removed. While a majority of the liver fragments were immediately frozen in liquid nitrogen some 127 
of them were rapidly processed for appropriate histological staining. Collected tissues frozen in 128 
liquid nitrogen were subsequently stored at -80°C until use. All experimentswere performed 129 
according to national guidelines for the useof animals in biomedical research and approved by the 130 
local Ethics Committee in Animal Experiment of Rennes 1 University and Robert Debré Hospital. 131 
 132 
Plasma analyses.Immediately after collection, blood was centrifuged for 10 min at 1000g and 133 
plasma was stored at -20°C until assay. Plasma activity of alanine aminotransferase (ALT) and 134 
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aspartate aminotransferase (AST), total cholesterol, triglycerides and glucose levels were measured 135 
on an automatic analyzer AU2700 (Olympus Diagnostics, Rungis, France) with Olympus 136 
commercial Kits OSR6107, OSR6109, OSR6116, OSR6133 and OSR6121, respectively.  137 
 138 
Liver histology. To evaluate necrosis, inflammation and steatosis, liver fragments were fixed in 10% 139 
neutral formalin and embedded in paraffin. Then, 4-µm thick sections were cut and stained with 140 
hematoxylin-eosin (H&E). All these sections were thoroughly examined by an experienced 141 
pathologist (V.T.-S.).  The amount of hepatic steatosis in ob/ob and the classification of this lesion 142 
into 3 different categories (i.e. microvesicular, mediovesicular and macrovacuolar) were determined 143 
as recently described (Trak-Smayra et al., 2011).     144 
 145 
RNA extraction and gene expression profiling.For the microarrays, total RNA extraction, linear T7-146 
based amplification step, hybridization procedure, detection and read out of the fluorescence signals 147 
were carried out by Miltenyi Biotec GmbH (Bergisch Gladbach, Germany). Total RNA was 148 
extracted from liver samples using a standard RNA extraction protocol (Trizol) and quality-checked 149 
with an Agilent 2100 Bioanalyzer platform. All RNA samples revealed RNA Integrity Number 150 
(RIN) values between 7.2 and 8. Further information on T7-based amplification, Cy3-labeling, 151 
hybridization of the Agilent microarray and detection of the fluorescent signals is given in the 152 
Supplementary Data.  153 
 154 
Analysis and data mining of microarray data. Gene expression data were analyzed using Feature 155 
Extraction and GeneSpring softwares (Agilent Technologies) and further analyzed using R-based 156 
array tools, as previously described (Sulpice et al., 2013). Agilent Feature Extraction Software was 157 
used to read out and process the microarray image files. This software determines feature intensities 158 
(including background subtraction), rejects outliers and calculates statistical confidences. Features 159 
that were not positive and significant or below the background signal were filtered out. Microarray 160 
data were normalized by using the 75th percentile shift normalization algorithm. Differentially 161 
expressed genes were identified by a two-sample univariate t-test and a random variance model as 162 
previously described (Coulouarn et al., 2012). Clustering analysis was done using Cluster 3.0 and 163 
TreeView 1.6 with uncentered correlation and average linkage options. Enrichment for specific 164 
biological functions or canonical pathways was evaluated by using gene ontology annotations, as 165 
described previously (Coulouarn et al., 2012). Gene set enrichment analysis (GSEA) was performed 166 
using the Java-tool developed at the Broad Institute (Cambridge, MA, USA). Microarray data were 167 
submitted to the gene expression omnibus (GEO) database (www.ncbi.nlm.nih.gov/geo; 168 
GSE49195). 169 
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 170 
Real-time quantitative PCR (RT-qPCR) analysis. In order to study the hepatic mRNA expression of 171 
selected genes, cDNAs were preparedby reverse transcription of 1 µg of total RNA using theHigh 172 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Courtaboeuf, France). cDNAswere 173 
thus amplified with specific primers using the Power SYBRGreen PCR Master Mix (Applied 174 
Biosystems), in an ABI Prism 7900 instrument (Applied Biosystems). Further information on PCR 175 
analysis is provided in the Supplementary Data.  176 
 177 
Statistical analysis. Data are presented as means ± SEM (standard error of mean). In order to assess 178 
statistical significances for body weight, plasma parameters and hepatic mRNA expression of 179 
selected genes, a two-way Analysis of variance (ANOVA) was performed with the factors of 180 
genotype (G) and drug mixture treatment (T). Individual means were compared with the post hoc 181 
Bonferroni test.   182 
  183 
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Results 184 
 185 
Body weight, plasma parameters and liver histology  186 
Body weight was measured on a regular basis for each mouse so that the gain of body weight 187 
could be calculated over the 4-month period of treatment.  Body weight was 31.2 ± 1.0 and 60.6 ± 188 
1.0 g, respectively in untreated lean and obese mice at the end of the treatment. The gain of body 189 
weight was higher in obese mice compared to lean mice and the treatment significantly modified 190 
this parameter (Table 1). However, it was either decreased, unchanged or increased depending in the 191 
different groups with no dose-dependent effect (Table 1).  192 
Some plasma parameters were measured at the end of the treatment. When compared to lean 193 
mice, untreated ob/ob mice presented higher levels of plasma ALT, AST and total cholesterol but 194 
normal levels of plasma triglycerides (Table 1), as previously reported (Fromenty et al., 2009; 195 
Lindström, 2007; Massart et al., 2012). In addition, the obese mice did not present hyperglycemia 196 
(Table 1), which was consistent with previous data showing that the diabetic state of ob/ob mice 197 
ameliorated with age (Fromenty et al., 2009; Lindström, 2007). Interestingly, treatment with the 198 
drug mixtures significantly modified the plasma levels of total cholesterol and ALT (Table 1). This 199 
was particularly evident in ob/ob mice treated with the cocktail containing 106 ng/l of each drug 200 
since this group of animals presented the highest plasma levels of total cholesterol and ALT (Table 201 
1).  202 
Liver histology was also studied at the end of the treatment in mice treated or not with the 203 
cocktails containing 105 and 106 ng/l of each drug. There were no histological alterations in lean 204 
mice whatever the groups of animals (data not shown). Slight necroinflammation was observed in 205 
untreated obese mice (data not shown), which could explain higher levels of plasma AST and ALT 206 
(Begriche et al., 2008; Trak-Smayra et al., 2011). However, treatment with the drug mixture did not 207 
aggravate the histological score of necroinflammation (data not shown).  208 
Hepatic steatosis was observed in all obese mice (Supplementary Table 1) but this lesion was 209 
absent in lean mice, treated or not with the cocktails (data not shown). Although the percentage of 210 
hepatocytes with steatosis was unchanged by the treatment in ob/ob mice, a lower proportion of 211 
microvesicular steatosis was observed in obese mice treated with the cocktail containing 106 ng/l of 212 
each drug (Supplementary Table 1). Accordingly, the fat droplets were larger in treated ob/ob mice 213 
when compared to the controls (Fig. 1). 214 
 215 
Microarray analysis 216 
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Gene expression profiling was carried out in order to determine whether the cocktail containing 217 
106 ng/l of each drug induced transcriptional changes in the livers of lean and obese mice. 218 
Unsupervised microarray analysis demonstrated that the cocktail significantly modified the hepatic 219 
expression of 280 and 284 genes (P<0.05; fold-change>1.5), respectively in lean and obese mice. 220 
Among these genes, only 21 were dysregulated in both genotypes thus suggesting that drug-induced 221 
transcriptional changes were tightly dependent of the genetic background. Table 2 provides the top 222 
10 well-annotated genes that were up or down-regulated by the cocktail in lean and obese mice. 223 
Interestingly, when a gene ontology analysis was performed, circadian rhythm was found as the 224 
only functional category significantly enriched for the hepatic genes differentially expressed by the 225 
cocktail in both lean and obese mice (Supplementary Table 2). In addition, this analysis indicated 226 
that the functional categories were linked to biosynthetic processes and transcription factor activity 227 
in lean mice and to cell cycle and cytoskeleton for ob/ob mice (Supplementary Table 2).  228 
Although this was not the main goal of this study, our unsupervised microarray analysis allowed us 229 
to determine the differential hepatic gene expression between lean and ob/ob mice. Our analysis 230 
identified 2,434 non-redundant genes that were differentially expressed between lean and obese 231 
mice (P<0.001; fold-change>2; data not shown). As previously reported (Fromenty et al., 2009; 232 
Yang et al., 2010), ob/ob mice were characterized by an increased expression of many genes 233 
involved in lipid synthesis, such as Elovl7 (x15.9), Scd2 (x12.7), Agpat9 (x8.3), Elovl6 (x7.7), 234 
Gpam (x5.3), Fasn (x4.6), Acaca (x4.6), Acly (x4.2), Pparg (x4.0) and Thrsp (x3.1). Moreover, 235 
there was in ob/ob mice a profound up- or down-regulation of the hepatic expression of several 236 
genes involved in the circadian rhythm such as Dbp (x14.3), Per3 (x7.1), Clock (x0.49), Arntl (also 237 
referred to as Bmal1) (x0.42) and Cry1 (x0.28). Interestingly, a recent study carried out in ob/ob 238 
mice reported lower hepatic expression of the last three genes compared to wild-type mice when the 239 
animals were investigated at zeitgeber times similar to our investigations (i.e. zeitgeber times 2 to 6) 240 
(Ando et al., 2011).  In order to validate the whole data set obtained from our microarray analysis, a 241 
GSEA was performed using independent hepatic gene expression profiles from ob/ob and lean mice 242 
(Sharma et al. 2010), uploaded from the GEO database (GSE20878). Importantly, GSEA 243 
demonstrated that up- and down-regulated genes in ob/ob livers identified in our study were 244 
significantly enriched in the respective gene profiles of ob/ob and lean mice from the independent 245 
GSE20878 dataset (Supplementary Fig. 1). 246 
 247 
mRNA expression of specific genes 248 
Some genes of interest were selected to determine by RT-qPCR their hepatic expression in mice 249 
treated or not with the cocktail containing the 11 drugs at concentrations ranging from 10 to 106 250 
ng/l. Since the gene ontology analysis pointed a specific dysregulation of genes involved in the 251 
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circadian rhythm in lean and obese mice, the expression of Bmal1, Clock, Dbp, Npas2, Per1, Per2, 252 
Per3, and Cry1 was studied in all groups of mice. As shown in Fig. 2, the drug cocktail presented a 253 
significant effect on gene expression, which was either decreased (Bmal1, Clock, Npas2, Cry1) or 254 
increased (Dbp, Per1, Per2, Per3). A clear dose-effect response was observed in lean and/or obese 255 
mice for the expression of all these genes. Moreover, drug mixture and obesity presented an additive 256 
effect on circadian gene expression. Importantly, the cocktail presented a significant effect on 257 
Bmal1, Dbp, Npas2, Per2, Per3, and Cry1 expression when it contained as low as 102 and 103 ng/l 258 
of each drug in the mixture (Fig. 2). For these concentrations, it could be estimated that each drug 259 
was administered to mice at the respective doses of 20 and 200 ng/kg/d, when considering the daily 260 
intake of water and the body weight of the animals.  261 
Because our gene expression profiling was performed on male mice solely, we next validated 262 
our results on female mice. To this end, an independent series of lean and ob/ob female mice was 263 
treated or not for 4 months with mixtures containing 104, 105 and 106 ng/l of each drug, as described 264 
in the Methods section. Interestingly, the profiles of drug-induced modification of circadian liver 265 
gene expression were about similar to those observed in male mice, except for Per1 (Fig. 3). It was 266 
noteworthy, however, that the effect of obesity on the hepatic expression of these genes was less 267 
pronounced in female mice (Fig. 3) when compared to males (Fig. 2). We also noticed that the liver 268 
expression of the circadian genes was in general higher in female mice, especially in wild-type 269 
animals (Supplementary Fig. 2), which was consistent with a recent study (Xu et al., 2012).  270 
Finally, we determined the hepatic expression of several genes not directly related to circadian 271 
rhythm such as Alas1, Arrdc3, Mt1, Mt2, Usp2 and Atp2b2, the expression of which was found 272 
dysregulated in the microarray analysis performed in male mice treated with the highest doses of the 273 
drugs (Table 2). Interestingly, a dose-effect response was in general observed for the expression of 274 
these 6 genes (Fig. 4). However, in female mice, only the expression of Arrdc3 and Usp2 was found 275 
to be comparable when compared to male mice (data not shown).   276 
  277 
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Discussion 278 
 279 
This study showed for the first time that chronic oral exposure to low doses of pharmaceuticals 280 
disturbed the hepatic expression of genes involved in circadian rhythm in mice. These 281 
transcriptional effects were dose-dependent and particularly robust since they were found in lean 282 
and obese male mice but also in female animals of both genotypes. In male mice, and to a lesser 283 
extent in female mice, drug mixture and obesity presented an additive effect on the expression of 284 
circadian genes such as Dbp, Per2 and Per3. Moreover, the expression of some circadian genes was 285 
dysregulated when the drinking water contained the 11 drugs at concentrations as low as 102 and 103 286 
ng/l. Such exposure corresponded to a daily intake of about 20 to 200 ng/kg/d. Hence, our data 287 
indicated that a mixture of pharmaceutical contaminants can alter the expression of hepatic genes at 288 
concentrations that can be found in drinking water. Indeed, for some drugs such as APAP, caffeine, 289 
carbamazepine, ibuprofen and phenazone, several hundreds of ng/l were found in tap water in 290 
previous studies (Daughton and Ternes, 1999; Mompelat et al., 2009). 291 
A “whole mixture approach” was used in this study, and thus our investigations were not 292 
designed to determine which drug(s) could be involved in these hepatic effects, in particular on the 293 
expression of circadian genes. Nevertheless, it is noteworthy that some drugs such as prednisolone 294 
(Koyanagi et al., 2006), 5-fluorouracil (Terazono et al., 2008), interferon- (Shinohara et al., 2008) 295 
and caffeine (Oike et al., 2011; Sherman et al., 2011) can disturb in liver the expression of genes 296 
involved in circadian rhythm. However, apart from caffeine, no information was found in the 297 
literature regarding this issue for the other drugs contained in the mixture. Although caffeine could 298 
have induced the genomic effects reported in our study, it is noteworthy that studies reporting 299 
caffeine-induced altered hepatic expression of clock genes were performed with much higher doses 300 
(from 3.5 to ca. 75 mg/kg/d) (Oike et al., 2011; Sherman et al., 2011). Thus, further investigations 301 
by treating mice with each drug separately would be needed to determine which component(s) of 302 
the mixture could alter the liver expression of clock genes when administered at very low doses. 303 
However, it is possible that the deleterious effects of the mixture uncovered in the present study 304 
might have been less significant with each individual drug (or might not have been observed), as 305 
suggested by some investigations in other experimental models (Christiansen et al., 2009; 306 
Kortenkamp et al., 2007). Interestingly, some of the drugs included in the cocktails belong to the 307 
same pharmacological classes (mainly nonsteroidal anti-inflammatory drugs and antibiotics). 308 
Therefore, it would be worth finding out whether the genomic effects detected in this study could be 309 
attributed to a particular drug class. 310 
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Although the expression of hepatic genes was disturbed in mice treated for 4 months with the 311 
cocktails containing 102 and 103 ng/l of each drug, these concentrations did not change the plasma 312 
parameters assessed in this study, namely ALT, AST, glucose, triglycerides and total cholesterol. 313 
Thus, the effects on gene expression observed in treated mice with these doses were not associated 314 
with significant hepatic cytolysis and systemic alterations of lipid homeostasis. Therefore, changes 315 
incircadian gene expression observed for these doses might not be functionally significant.It would 316 
be interesting to determine whether a much longer exposure to these low concentrations of 317 
pharmaceuticals could have harmful effects on liver biology and integrity beyond the alterations of 318 
gene expression. Furthermore, some selected circadian genes (e.g. Bmal1, Per1, Per2) could be 319 
useful markers for further investigations specifically designed to look for potential genomic effects 320 
of individual drug (or subset of drugs) included in the mixture. 321 
It is now acknowledged that disturbances of circadian rhythmicity can promote different 322 
metabolic disorders and chronic diseases such as dyslipidemia, insulin resistance, obesity and 323 
cardiovascular diseases (Duez and Staels, 2008; Maury et al., 2010; Prasai et al., 2008). Moreover, 324 
some studies showed that liver-specific deletion of genes involved in the liver clock could disturb 325 
glucose and lipid homeostasis (Lamia et al., 2008; Tao et al., 2011). In this study, however, the 326 
genomic response to drug exposure was investigated only in the liver. Hence, further investigations 327 
would be required to determine whether an altered expression of clock genes could also be observed 328 
in other tissues such as the CNS and in tissues playing a key role in carbohydrate and lipid 329 
homeostasis. Different time points of the light-dark cycle should also be studied during these 330 
investigations.  331 
In this study, the 4-month treatment with the cocktail containing 106 ng/l of each drug 332 
significantly increased plasma ALT and total cholesterol and changed the pattern of hepatic 333 
steatosis in ob/ob mice, whereas these effects were not observed in wild-type mice. For this dosage, 334 
the hepatic expression of most circadian genes in ob/ob mice was the highest, or the lowest, among 335 
the different groups of animals. Interestingly, the daily intake corresponding to this dose (ca. 0.2 336 
mg/kg/d) was well below the pharmacological dosages for all drugs included in the mixture. Indeed, 337 
the daily dosage of these drugs is comprised between a few mg/kg/d for diclofenac and 338 
roxithromycin to 40 and 60 mg/kg/d for salicylic acid and APAP, respectively. Importantly, some of 339 
these drugs such as APAP, diclofenac, ibuprofen and salicylate can be taken over the long-term (i.e. 340 
several months) for the treatment of inflammatory diseases or chronic pain (Kuffner et al., 2006; 341 
Schaffer et al., 2006), which are often observed in obese patients (Guh et al. 2009; Wright et al. 342 
2010). Thus, our work could also be relevant for obese patients with multiple drug prescriptions, 343 
since obesity appears to increase the risk of hepatotoxicity, at least for some drugs (Fromenty, 2013; 344 
Massart et al., 2012). Further investigations will be needed to determine whether the genomics 345 
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changes observed in this study could be involved in higher plasma ALT and total cholesterol 346 
observed in ob/ob mice. 347 
In conclusion, our study showed for the first time that chronic exposure to trace 348 
pharmaceuticals was able to disturb the hepatic expression of genes involved in circadian rhythm in 349 
lean and obese mice. This effect was dose-dependent and the expression of some circadian genes 350 
was already dysregulated when the drinking water contained the 11 drugs at concentrations as low 351 
as 102 and 103 ng/l. Moreover, drug mixture and obesity presented an additive effect on this gene 352 
expression. Because some of the 11 drugs can be found in the drinking water at such concentrations 353 
(e.g. APAP, caffeine, carbamazepine, ibuprofen, phenazone) further investigations would be needed 354 
to determine whether our data could be extrapolated to human populations exposed to 355 
pharmaceutical contaminants, in particular in countries with high prevalence of obesity.  356 
 357 
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Table 1.  500 
Body weight gain and plasma parameters in the different groups of mice at the end of the treatment. 501 
Animals  
 
Treatment 
 
Body weight 
gain 
(g) 
Glucose 
(mM) 
Total 
cholesterol 
(mM) 
Triglycerides 
(mM) 
ALAT 
(UI/L) 
ASAT 
(UI/L) 
Lean  
 
0 11.1 ± 0.8 9.6 ± 0.9 2.49 ± 0.12 1.42 ± 0.17 86 ± 15 194 ± 50 
 
 
10 ng/l 9.8 ± 2.1 9.2 ± 0.6 2.21 ± 0.09 1.00 ± 0.09 90 ± 13 147 ± 25 
 
 
102 ng/l 11.4 ± 0.7 8.8 ± 0.4 2.28 ± 0.08 1.21 ± 0.16 76 ± 9 164 ± 30 
 
 
103 ng/l 10.5 ± 0.4 9.4 ± 0.4 2.31 ± 0.09 1.15 ± 0.08 113 ± 26 187 ± 24 
 
 
104 ng/l 11.9 ± 0.5 10.0 ± 0.4 2.43 ± 0.05 1.29 ± 0.10 71 ± 5 145 ± 23 
 
 
105 ng/l 12.8 ± 0.3 10.2 ± 0.6 2.67 ± 0.08 1.34 ± 0.03 147 ± 27 189 ± 14 
 
 
106 ng/l 11.3 ± 0.6 9.9 ± 0.5 2.53 ± 0.09 1.35 ± 0.18 101 ± 13 159 ± 24 
ob/ob 
 
0 30.4 ± 0.8 7.2 ± 0.7 7.88 ± 0.38 1.27 ± 0.12 708 ± 50 451 ± 24 
 
 
10 ng/l 27.7 ± 1.5 10.2 ± 3.1 7.43 ± 0.65 1.12 ± 0.09 672 ± 62 674 ± 105 
 
 
102 ng/l 31.7 ± 1.6 8.1 ± 0.9 7.81 ± 0.29 1.06 ± 0.02 674 ± 75 587 ± 85 
 
 
103 ng/l 30.0 ± 0.6 9.5 ± 1.2 7.73 ± 0.44 1.16 ± 0.08 533 ± 58† 372 ± 42 
 
 
104 ng/l 31.3 ± 0.9 8.9 ± 0.7 8.16 ± 0.32 1.19 ± 0.08 683 ± 43 748 ± 230 
 
 
105 ng/l 33.3 ± 0.5 9.8 ± 1.0 8.46 ± 0.29 1.07 ± 0.03 844 ± 104 759 ± 133 
 
 
106 ng/l 29.1 ± 0.9 9.4 ± 0.5 8.83 ± 0.28† 1.29 ± 0.05 936 ± 56† 702 ± 76 
Two-way 
ANOVA 
analysis 
 
G,T 
 
G,T 
 
G,T,GxT G 
Note: Plasma parameters were determined in the fed state. Body weight gain was calculated for each mouse over 502 
the 4 months of treatment. Results are mean ± SEM for 5 to 7 mice. Statistical analysis was performed with a two-503 
way ANOVA: G, effect of genotype, T, effect of treatment, GxT, interaction between genotype and treatment. 504 
Individual means were then compared with the post hoc Bonferroni test. †Significantly different from untreated 505 
mice of the same genotype (P<0.05).  506 
  507 
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Table 2.  508 
Top 10 well-annotated genes that were up or down-regulated in liver of wild-type and ob/ob mice treated with 509 
the cocktail containing 106 ng/l of each drug. 510 
Up-regulated in both lean 
and ob/ob micea 
Name  (Accession number) Gene ontologyb 
Dbp (lean 3.70 ; ob 2.08)c D site albumin promoter binding protein (NM_016974) 
Circadian rhythm. Positive regulation of transcription from 
RNA polymerase II promoter  
Alas1 (lean 2.56 ; ob 1.52) Aminolevulinic acid synthase 1 
(NM_020559) 
Biosynthetic process. Heme biosynthetic process 
Ypel1 (lean 1.89 ; ob 1.54) Yippee-like 1 (Drosophila) (NM_023249) Negative regulation of protein kinase B signaling cascade. 
Regulation of myelination 
Gnat1 (lean 1.79 ; ob 1.79) Guanine nucleotide binding protein, alpha 
transducing 1 (NM_008140) 
Adenylate cyclase-modulating G-protein coupled receptor 
signaling pathway. Cell proliferation 
Pfkfb3 (lean 1.79 ; ob 1.59) 6-Phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3 (NM_133232) 
Fructose 2,6-biphosphate metabolic process. Phosphorylation 
Arrdc3 (lean 1.79 ; ob 1.52) Arrestin domain containing 3 
(NM_001042591) 
Fat pad development. Negative regulation of heat generation 
Down-regulated in both 
lean and ob/ob mice 
Name (Accession number) Gene ontology 
Cry1 (lean 0.38 ; ob 0.65) Cryptochrome 1 (photolyase-like) 
(NM_007771) 
Circadian rhythm. DNA repair 
Hmgcs1 (lean 0.45 ; ob 0.61) 3-Hydroxy-3-methylglutaryl-Coenzyme A 
synthase 1 (AK078743) 
Cholesterol biosynthetic process. Isoprenoid biosynthetic 
process 
Trim27 (lean 0.45 ; ob 0.63) Tripartite motif-containing 27 
(AK049314) 
Interferon gamma secretion. Negative regulation of adaptive 
immune response 
Cstad (lean 0.50 ; ob 0.63) CSA-conditional, T cell activation-
dependent protein (NM_030137) 
Mitochondrial membrane organization  
Avpr1a (lean 0.54 ; ob 0.67) Arginine vasopressin receptor 1A 
(NM_016847) 
Calcium-mediated signaling. Elevation of cytosolic calcium 
ion concentration 
Lonrf3 (lean 0.56 ; ob 0.58) LON peptidase N-terminal domain and 
ring finger 3 (NM_028894) 
Proteolysis 
Cdca2 (lean 0.56 ; ob 0.61) Cell division cycle associated 2 
(NM_175384) 
Cell cycle. Cell division 
Arntl (lean 0.57 ; ob 0.36) Aryl hydrocarbon receptor nuclear 
translocator-like (NM_007489) 
Circadian regulation of gene expression. Circadian rhythm 
Chka (lean 0.60 ; ob 0.56) Choline kinase alpha (NM_013490) CDP-choline pathway. Glycerophospholipid biosynthetic 
process 
Cxadr (lean 0.62 ; ob 0.56) Coxsackie virus and adenovirus receptor 
(NM_009988) 
Actin cytoskeleton reorganization. AV node cell to bundle of 
His cell communication  
Up-regulated only in lean 
mice 
Name Gene ontology 
Cfd (4.35) Complement factor D (adipsin) 
(NM_013459) 
Complement activation, alternative pathway. Innate immune 
response 
H19 (3.85) H19 fetal liver mRNA (AK003142) Negative regulation of cell proliferation. Regulation of gene 
expression 
Tppp3 (2.94) Tubulin polymerization-promoting protein 
family member 3 (NM_026481) 
Microtubule bundle formation 
Inhbb (2.63) Inhibin beta-B (NM_008381) Activin receptor signaling pathway. Cellular response to 
cholesterol 
Kif23 (2.50) Kinesin family member 23 (NM_024245) Spindle midzone assembly involved in mitosis 
E2f7 (2.44) E2F transcription factor 7 (NM_178609) Cell cycle. Chorionic trophoblast cell differentiation 
Pdlim3  (2.44) PDZ and LIM domain 3 (NM_016798) Actin filament organization. Heart development 
Igfbp6 (2.38) Insulin-like growth factor binding protein 
6 (X81584) 
Regulation of cell growth 
 Esm1 (2.33) Endothelial cell-specific molecule 1 
(NM_023612) 
Biological process. Regulation of cell growth 
Il1rap (2.33) Interleukin 1 receptor accessory protein 
(NM_008364) 
Cytokine-mediated signaling pathway. Innate immune 
response 
Down-regulated only in 
lean mice 
Name Gene ontology 
Fos (0.19)2 FBJ osteosarcoma oncogene 
(NM_010234) 
Cellular response to cellular calcium ion. Cellular response to 
extracellular stimulus. 
Nr4a1 (0.21) Nuclear receptor subfamily 4, group A, 
member 1 (NM_010444) 
Apoptotic process. Cell migration involved in sprouting 
angiogenesis  
Egr1 (0.31) Early growth response 1 (NM_007913) Bone morphogenetic protein signaling pathway. Cellular 
20 
 
response to gamma radiation 
Dusp1 (0.36) Dual specificity phosphatase 1 
(NM_013642) 
Cell cycle. Dephosphorylation 
Igh-VJ558 (0.40) Immunoglobulin heavy chain (J558 
family) (XM_001474025) 
 
Igfbp1  (0.40) Insulin-like growth factor binding protein 
1 (NM_008341) 
Regulation of cell growth 
Fam65b (0.42) Family with sequence similarity 65, 
member B (NM_029679) 
Biological process 
Zfp36 (0.44) Zinc finger protein 36 (NM_011756) 3’-UTR-mediated mRNA stabilization. Intracellular protein 
kinase cascade 
 Fam110c (0.45) Family with sequence similarity 110, 
member C (NM_027828) 
Positive regulation of cell migration. Positive regulation of 
protein kinase B signaling cascade 
Slc34a2 (0.46) Solute carrier family 34 (sodium 
phosphate), member 2 (NM_011402) 
Cellular phosphate ion homeostasis. In utero embryonic 
development  
Up-regulated only in 
ob/ob mice 
Name Gene ontology 
Clec2d (2.86) C-type lectin domain family 2, member d 
(NM_053109) 
Cellular defense response. Negative regulation of osteoclast 
differentiation 
Usp2 (2.78) Ubiquitin specific peptidase 
(NM_198092) 
Cell cycle. Muscle organ development 
Mt2 (2.63) Metallothionein 2 (NM_008630) Cellular response to drug. Cellular zinc ion homeostasis 
Upp2 (2.56) Uridine phosphorylase 2 (NM_029692) Metabolic process. Nucleoside metabolic process 
Mt1 (2.44) Metallothionein 1 (NM_013602) Cellular metal ion homeostasis. Cellular response to 
chromate 
Krt20 (2.33) Keratin 20 (NM_023256) Apoptotic process. Cellular response to stress 
Rgs16 (2.27) Regulator of G-protein signaling 16 
(NM_011267) 
G-Protein coupled receptor signaling pathway. Negative 
regulation of signal transduction 
Car3 (2.08) Carbonic anhydrase 3 (AK075630) One-carbon metabolic process. Response to oxidative stress 
Grm8 (1.92) Glutamate receptor, metabotropic 8 
(NM_008174) 
Adenylate cyclase inhibiting G-protein coupled glutamate 
receptor signaling pathway. G-protein coupled  receptor 
signaling pathway 
Cdc6 (1.85) Cell division cycle 6 homolog (S. 
cerevisiae) (NM_011799) 
Cell cycle. Cell division  
Down-regulated only in 
ob/ob mice 
Name Gene ontology 
Moxd1 (0.18) Monooxygenase, DBH-like 1 
(NM_021509) 
Catecholamine metabolic process. Oxidation-reduction 
process 
Hsd3b5 (0.18) Hydroxy-delta-5-steroid dehydrogenase, 3 
beta- and steroid delta-isomerase 5 
(NM_008295) 
Oxidation-reduction process. Steroid biosynthetic process 
Man2a2 (0.40) Mannosidase 2, alpha 2 (NM_172903) Carbohydrate metabolic process. Mannose metabolic process 
 Usp26 (0.45) Ubiquitin specific peptidase 26 
(NM_031388) 
Protein deubiquitination. Proteolysis 
Gadd45g (0.45) Growth arrest and DNA-damage-
inducible 45 gamma (NM_011817) 
Activation of MAPKK activity. Apoptotic process 
Atp2b2 (0.45) ATPase, Ca2+ transporting, plasma 
membrane 2 (NM_009723) 
ATP catabolic process. Calcium ion export 
Ppp1r9a (0.46) Protein phosphatase 1, regulatory 
(inhibitor) (NM_181595) 
Actin filament organization. Calcium-mediated signaling  
 Kalrn (0.47) Kalirin, RhoGEF kinase (AK051053)  Axonogenesis. Intracellular signal transduction 
 Murc (0.48) Muscle-related coiled-coil protein 
(NM_026509) 
Cardiac myofibril assembly. Cell differentiation  
Elovl3 (0.48) Elongation of very long chain fatty acids-
like 3 (NM_007703) 
Fatty acid biosynthetic process. Fatty acid elongation, 
monounsaturated fatty acid 
Note:aLess than 10 genes were found to be modulated by the drug mixture in this category. bThe first 2 terms were selected by 511 
using the Amigo Gene Ontology website, with “Mus musculus” and “Biological process” as filters. cThe number in parentheses 512 
is the fold change given by the microarray analysis. 513 
 514 
 515 
 516 
 517 
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 519 
Legends to the figures 520 
 521 
 522 
 523 
Figure 1. Hepatic steatosis in obese ob/ob mice treated or not with the cocktail containing 106 ng/l 524 
of each drug. Liver sections were stained with H&E and pictures were taken at 200x magnification.  525 
Mice presented in panels A, B and C are those numbered 1, 14 and 18 in Supplementary Table 1.  526 
22 
 
 527 
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 528 
Figure 2. Hepatic mRNA expression of 8 circadian genes in male lean and obese mice treated or not 529 
with the cocktail containing the 11 drugs at concentrations ranging from 10 to 106 ng/l. Results are 530 
mean ± SEM for 5 to 7 mice. Statistical analysis was performed with a two-way ANOVA: G, effect 531 
of genotype, T, effect of treatment, GxT, interaction between genotype and treatment. Individual 532 
means were then compared with the post hoc Bonferroni test. †Significantly different from 533 
untreated mice of the same genotype (P<0.05). 534 
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Figure 3. Hepatic mRNA expression of 8 circadian genes in female lean and obese mice treated or 536 
not with the cocktail containing the 11 drugs at concentrations ranging from 104 to 106 ng/l. Results 537 
are mean ± SEM for 4 to 8 mice. Statistical analysis was performed with a two-way ANOVA: G, 538 
effect of genotype, T, effect of treatment, GxT, interaction between genotype and treatment. 539 
Individual means were then compared with the post hoc Bonferroni test. †Significantly different 540 
from untreated mice of the same genotype (P<0.05). 541 
 542 
 543 
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 544 
 545 
Figure 4. Hepatic mRNA expression of 6 non-circadian genes in male lean and obese mice treated 546 
or not with the cocktail containing the 11 drugs at concentrations ranging from 10 to 106 ng/l. 547 
Results are mean ± SEM for 5 to 7 mice. Statistical analysis was performed with a two-way 548 
ANOVA: G, effect of genotype, T, effect of treatment, GxT, interaction between genotype and 549 
treatment. Individual means were then compared with the post hoc Bonferroni test. †Significantly 550 
different from untreated mice of the same genotype (P<0.05). 551 
